UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~September~~December 2130, 2010

SINOBIOPHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada	333-144910	26-3002371
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

8 Zhong Tian Road,

Nantong City, Jiangsu Province, People’s Republic of China 226009

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (86) 51-385328336

Copies to:

Gregory Sichenzia, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Phone: (212) 930-9700

Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1Item 8.01 Other Events

~~Item~~As 2previously reported on Sinobiopharma, Inc.~~02 Results~~’s (the “Company”) Current Report on Form 8-K filed on June 30, 2010, on May 30, 2010, the board of ~~Operations~~directors ~~and~~of ~~Financial~~the ~~Condition~~Company resolved that the company would issue Ms. Hoki Luk 300,000 shares of the Company’s common stock as compensation for serving as an independent director.

On ~~September~~December 2130, 2010, ~~Sinobiopharma,~~the ~~Inc.,~~board aof ~~Nevada~~directors ~~corporation (the “Company”)~~approved, ~~announced~~and ~~its~~Ms. ~~results~~Luk ofagreed, ~~operations~~to ~~for~~waive ~~the~~her ~~fiscal~~rights ~~year~~to ~~ended~~the ~~May 31~~300,000 ~~2010. A~~shares ~~copy~~and ofinstead ~~the~~receive ~~related~~$10,000 ~~press~~in ~~release~~cash, isto ~~being~~be ~~filed~~paid ason ~~Exhibit~~or ~~99.1~~before toJanuary13, ~~this~~2011, ~~Form~~in ~~8-K~~full ~~and~~satisfaction isof ~~incorporated~~compensation ~~herein~~for byher ~~reference~~services inas ~~its~~independent ~~entirety~~director.

The information in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99None.~~1 Press release dated September 21, 2010, issued by Sinobiopharma, Inc.~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Date: September 21, 2010
	Date: December 30, 2010
	SINOBIOPHARMA, INC.
	By:	/s/ Lequn Huang
		Lequn Huang
		Chief Executive Officer

Filing Compare · Sinobiopharma, Inc.